Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology (2024)

Advanced Search

Stephen Schauer, Balazs Toth, Julie Lee, Lee A Honigberg, Vidya Ramakrishnan, Jenny Jiang, Gwendlyn Kollmorgen, Anna Bayfield, Norbert Wild, Jennifer Hoffman, Ryan Ceniceros, Michael Dolton, Sandra Sanabria Bohorquez, Casper C Hoogenraad, Kristin R Wildsmith, Edmond Teng, Cecilia Monteiro, Veronica Anania, Felix Yeh

doi: https://doi.org/10.1101/2024.04.18.24306056

  • Abstract
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF

Abstract

INTRODUCTIONSemorinemab, an anti-tau monoclonal antibody, was evaluated in two Phase II trials as a disease-modifying treatment for Alzheimer's disease (AD). Plasma and cerebrospinal fluid (CSF) samples were collected from trial participants to evaluate the pharmacodynamic effects of semorinemab and elucidate its mechanism of action.METHODSQualified immunoassays were used to measure plasma and CSF biomarkers of tau, amyloidosis, glial activity, neuroinflammation, synaptic function, and neurodegeneration from participants enrolled in the Tauriel (NCT03289143) and Lauriet (NCT03828747) Phase II trials in prodromal-to-mild (P2M) and mild-to-moderate (M2M) AD. RESULTSSignificant increases in plasma phosphorylated Tau 181 (pTau181) and CSF Chitinase-3-like protein 1 (YKL-40) followed administration of semorinemab in both studies. In the Lauriet study, plasma glial fibrillary protein (GFAP) levels rose progressively over the study period in the placebo group, but remained stable over time with the administration of semorinemab. In contrast, this was not observed in the Tauriel study. Semorinemab had no consistent impact on other biomarkers of AD pathophysiology that were evaluated. DISCUSSIONSemorinemab engages and stabilizes plasma pTau181 in a manner consistent with previously reported data [1,2], and levels do not decrease after prolonged drug exposure. Increases to CSF YKL-40 suggest that semorinemab may stimulate microglia activation, while stabilization of plasma GFAP levels in Lauriet participants indicate that semorinemab may moderate reactive gliosis in M2M AD.

Competing Interest Statement

All authors are full-time employees and own stock in F. Hoffmann-La Roche Ltd. Edmond Teng is listed as a co-inventor on the patent for semorinemab.

Clinical Trial

NCT03289143, NCT03828747

Funding Statement

The study was funded by F. Hoffmann-La Roche Ltd and Genentech.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All of Ethics committees/IRB listed below gave ethical approval for the Tauriel (NCT03289143) study. [1] NeuroCentrix / Bellberry Human Research Ethics Committees [2] Royal Melbourne Hospital / Melbourne Health Human Research Ethics Committee [3] Royal Melbourne Hospital / Alfred Hospital Ethic Committee [4] Southern Neurology / Bellberry Human Research Ethics Committees [5] Universitair Ziekenhuis Brussel / Ethische Commissie Onderzoek UZ-KU Leuven [6] UZ Leuven / Ethische Commissie Onderzoek UZ-KU Leuven [7] AZ Groeninge / Ethische Commissie Onderzoek UZ-KU Leuven [8] Clinique de la Memoire de l'Outaoua / WCG Clinical [9] Toronto Sunnybrook Hospital / Sunnybrook Health Sciences REB [10] Toronto Memory Program (Neurolog / WCG Clinical [11] Bruyere Continuing Care / Bruyere Continuing Care REB [12] JBN Medical Diagnostic Services Inc. / WCG Clinical [13] Toronto Western Hospital / University Health Network Research Ethics Board [14] CCBR - Vejle - DK / Videnskabsetiske Komite for Region Nordjylland [15] CCBR - AAlborg - DK / Videnskabsetiske Komite for Region Nordjylland [16] Centre pour Personnes AAges / Comite de Protection des Personnes Sud-ouest et Outre-Mer IV [17] CHU Rennes - Pontchaillou / CPP Nord-Ouest III [18] CHU Strasbourg - Hopital Hautepierr / Comite de Protection des Personnes Sud-ouest et Outre-Mer IV [19] Hopital de la Timone / CPP Nord-Ouest III [20] Groupe Hospitalier Pitie-Salpetriere / CPP Nord-Ouest III [21] Hopital des Chapennes / CPP Nord-Ouest III [22] CHU de Lyon - Hopital Neurologique / CPP Nord-Ouest III [23] CHU Lille - Hopital Roger Salengro / Comite de Protection des Personnes Sud-ouest et Outre-Mer IV [24] Klinikum rechts der Isar der TU Muenchen / Ethikkommission der Fakultat fur Medizin der TU Munchen [25] Klinische Forschung Hannover-Mitte / Ethikkommission der Fakultat fur Medizin der TU Munchen [26] Universitatsklinikum Tuebingen / Ethikkommission der Fakultat fur Medizin der TU Munchen [27] Charite - Campus Berlin Buch, Experi / Ethikkommission der Fakultat fur Medizin der TU Munchen [28] Universitatsklinikum Ulm / Ethikkommission der Fakultat fur Medizin der TU Munchen [29] Azienda Ospedaliera Universitaria Po / Comitato etico dell'Azienda Policlinico Umberto I [30] Ospedale San Giovanni Calabita Fate / Comitato Etico Lazio 1 [31] I.R.C.C.S. Neuromed-Istituto Neurolo / Comitato Etico dell'I.R.C.C.S. Neuromed-Istituto Neurologico Mediterraneo [32] Azienda Ospedaliera Card. G. Panico / Comitato Etico della AUSL LE di Lecce [33] Jeroen Bosch Ziekenhuis / Stichting Beoordeling Ethiek Biomedisch Onderzoek [34] Brain Research Center / Stichting Beoordeling Ethiek Biomedisch Onderzoek [35] Centrum Medyczne NeuroProtect / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [36] Podlaskie Centrum Psychogeriatrii / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [37] NZOZ NEURO-KARD, Ilkowski i Par / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [38] Neuro-Care Gabriela Klodowska / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [39] Pratia MCM Krakow / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [40] PALLMED Sp. z o.o. / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [41] Centrum Medyczne AMED Warszawa / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [42] Osrodek Badan Klinicznych EUROME / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [43] NZOZ Wroclawskie Centrum Alzheim / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [44] Novo-Med Zielinski i wspolnicy Sp. j. / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [45] Hospital Perpetuo Socorro / La Fe Department de Salut [46] Hospital Universitario Reina Sofia / La Fe Department de Salut [47] Hospital Universitari i Politecnic La F / La Fe Department de Salut [48] Hospital de la Santa Creu i Sant Pau / La Fe Department de Salut [49] Fundacio ACE / La Fe Department de Salut [50] Hospital Universitario Dr. Peset / La Fe Department de Salut [51] Hospital Universitario Mutua de Terr / La Fe Department de Salut [52] Policlinica Gipuzkoa / La Fe Department de Salut [53] Hospital de Cantoblanco / La Fe Department de Salut [54] Clinica Universidad de Navarra / La Fe Department de Salut [55] Hospital Clinic de Barcelona / La Fe Department de Salut [56] Hospital Universitario Virgen Macare / La Fe Department de Salut [57] Sahlgrenska Universitetssjukhuset, M / Regionala etikprovningnamnden i Stockholm [58] Skanes Universitetssjukhus, Malmo / Regionala etikprovningnamnden i Stockholm [59] Re:Cognition Health Ltd (London) / London - Chelsea Research Ethics Committee [60] The National Hospital for Neurology / London - Chelsea Research Ethics Committee [61] Miami Jewish Health System, Inc / WCG Clinical [62] Southern Illinois University Neurolog / Springfield Committee for Research Involving Human Subjects [63] Neuropsychiatric Research Center of / WCG Clinical [64] Brain Matters Research / WCG Clinical [65] Empire Neurology, PC / Copernicus Group IRB [66] Alexian Brothers Medical Center - Ne / WCG Clinical [67] University of Alabama at Birmingham / WCG Clinical [68] JEM Research Institute / WCG Clinical [69] Synexus Clinical Research US, Inc. - O / Copernicus Group IRB [70] Albany Medical College / WCG Clinical [71] Perlmutter Cancer Center NYU Lango / Columbia University Medical Center IRB [72] Collier Neurologic Specialists, LLC / WCG Clinical [73] Emory University / WCG Clinical [74] Summit Research Network (Oregon) / WCG Clinical [75] Brigham and Women's Hospital / WCG Clinical [76] Premiere Research Institute / Copernicus Group IRB [77] KI Health Partners, LLC / Copernicus Group IRB [78] Bradenton Research Center, Inc. / Copernicus Group IRB [79] Bradenton Research Center, Inc. / WCG Clinical [80] The Memory Clinic / Copernicus Group IRB [81] Alzheimers Disease Center / Copernicus Group IRB [82] Collaborative Neuroscience Network / WCG Clinical [83] Pharmacology Research Institute / WCG Clinical [84] University of Rochester / WCG Clinical [85] Center for Memory and Aging / HealthPartners Institute Institutional Review Board [86] Molecular Neuroimaging / WCG Clinical [87] University of California - Irvine / University of California - Irvine IRB [88] Butler Hospital / Copernicus Group IRB [89] Stanford Hospital and Clinics / Stanford University - Human Subjects IRB [90] Rush University Medical Center-Chic / Rush University Medical Center - Office of Research Affairs [91] Advanced Memory Research Institut / WCG Clinical [92] AMR New Orleans, Formerly New Or / WCG Clinical [93] Neurology Clinic, PC / Copernicus Group IRB [94] Rhode Island Mood & Memory Resea / WCG Clinical [95] Pacific Research Network, Inc / WCG Clinical [96] Georgetown University Medical Cent / Georgetown University Hospital IRB [97] Alzheimer's Research and Treatment / WCG Clinical [98] Abington Neurological Associates / WCG Clinical All of Ethics committees/IRB listed below gave ethical approval for the Lauriet (NCT03828747) study. [1] Brain Matters Research / WCG Clinical [2] Synexus Clinical Research US, Inc. / WCG Clinical [3] Alexian Brothers Medical Center - Neuroscience Research Institute / WCG Clinical [4] Alzheimer's Research and Treatment Center / WCG Clinical [5] JEM Research Institute / WCG Clinical [6] Abington Neurological Associates, LTD / WCG Clinical [7] Neuropsychiatric Research Center of Southwest Florida / WCG Clinical [8] Alzheimers Disease Center / WCG Clinical [9] CHU Rennes - Pontchaillou / CPP Nord-Ouest III [10] Hopital de la Timone / CPP Nord-Ouest III [11] Groupe Hospitalier Pitie-Salpetriere / CPP Nord-Ouest III [12] Hopital Neurologique Bron / CPP Nord-Ouest III [13] Centrum Medyczne NeuroProtect / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [14] Podlaskie Centrum Psychogeriatrii / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [15] NZOZ NEURO-KARD, Ilkowski i Partnerzy Sp. Partn. Lek. / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [16] Osrodek Badan Klinicznych EUROMEDIS / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [17] NZOZ Wroclawskie Centrum Alzheimerowskie / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [18] NZOZ NOVO-MED / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej [19] KI Health Partners, LLC / WCG Clinical [20] Miami Jewish Health System, Inc / WCG Clinical [21] Southern Illinois University Neurology Clinic / Springfield Committee for Research Involving Human Subjects [22] Neurology Clinic, PC / WCG Clinical [23] Empire Neurology, PC / WCG Clinical [24] Collier Neurologic Specialists, LLC / WCG Clinical [25] Summit Headlands LLC / WCG Clinical [26] Brigham and Women's Hospital / WCG Clinical [27] Alphab Global Research / WCG Clinical [28] CenExel Collaborative Neuroscience Research / WCG Clinical [29] Pharmacology Research Institute / WCG Clinical [30] University of Rochester - PARENT / WCG Clinical [31] Center for Memory and Aging / HealthPartners Institute Institutional Review Board [32] Stanford Hospital and Clinics / Stanford University - Human Subjects IRB [33] CenExel Advanced Memory Research Institute of NJ / WCG Clinical [34] Pacific Research Network, Inc / WCG Clinical [35] Bradenton Research Center, Inc. / WCG Clinical [36] The Memory Clinic / WCG Clinical [37] Molecular Neuroimaging / WCG Clinical [38] Butler Hospital / WCG Clinical [39] Rush University Medical Center-Chicago / Rush University Medical Center - Office of Research Affairs [40] Rhode Island Mood & Memory Research Institute / WCG Clinical [41] AMR Knoxville, Formerly New Orleans Center for Clinical Research - Knoxville, an AMR company / WCG Clinical [42] Hopital des Chapennes / CPP Nord-Ouest III [43] Hospital Universitari i Politecnic La Fe / La Fe Department de Salut [44] Hospital de la Santa Creu i Sant Pau / La Fe Department de Salut [45] Fundacio ACE / La Fe Department de Salut [46] Hospital Universitario Dr. Peset / La Fe Department de Salut [47] Hospital Clinic de Barcelona / La Fe Department de Salut [48] Hospital Universitario Mutua de Terrasa / La Fe Department de Salut [49] Centrum Medyczne AMED Warszawa Zoliborz / Komisja Bioetyczna przy Dolnoslaskiej Izbie Lekarskiej

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Back to top

PreviousNext

PostedApril 19, 2024.

Download PDF

Data/Code

Email

Citation Tools

  • Facebook Like
  • Google Plus One

Subject Areas

All Articles

  • Addiction Medicine (317)

  • Allergy and Immunology (621)

  • Anesthesia (162)

  • Cardiovascular Medicine (2302)

  • Dentistry and Oral Medicine (280)

  • Dermatology (205)

  • Emergency Medicine (372)

  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (821)

  • Epidemiology (11640)

  • Forensic Medicine (10)

  • Gastroenterology (686)

  • Genetic and Genomic Medicine (3642)

  • Geriatric Medicine (342)

  • Health Economics (625)

  • Health Informatics (2337)

  • Health Policy (921)

  • Health Systems and Quality Improvement (872)

  • Hematology (337)

  • HIV/AIDS (762)

  • Infectious Diseases (except HIV/AIDS) (13215)

  • Intensive Care and Critical Care Medicine (761)

  • Medical Education (361)

  • Medical Ethics (101)

  • Nephrology (394)

  • Neurology (3398)

  • Nursing (193)

  • Nutrition (512)

  • Obstetrics and Gynecology (655)

  • Occupational and Environmental Health (655)

  • Oncology (1785)

  • Ophthalmology (528)

  • Orthopedics (212)

  • Otolaryngology (284)

  • Pain Medicine (227)

  • Palliative Medicine (66)

  • Pathology (441)

  • Pediatrics (1014)

  • Pharmacology and Therapeutics (423)

  • Primary Care Research (411)

  • Psychiatry and Clinical Psychology (3114)

  • Public and Global Health (6037)

  • Radiology and Imaging (1240)

  • Rehabilitation Medicine and Physical Therapy (721)

  • Respiratory Medicine (815)

  • Rheumatology (370)

  • Sexual and Reproductive Health (362)

  • Sports Medicine (319)

  • Surgery (390)

  • Toxicology (50)

  • Transplantation (171)

  • Urology (144)

Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology (2024)
Top Articles
Latest Posts
Article information

Author: Rueben Jacobs

Last Updated:

Views: 5664

Rating: 4.7 / 5 (57 voted)

Reviews: 80% of readers found this page helpful

Author information

Name: Rueben Jacobs

Birthday: 1999-03-14

Address: 951 Caterina Walk, Schambergerside, CA 67667-0896

Phone: +6881806848632

Job: Internal Education Planner

Hobby: Candle making, Cabaret, Poi, Gambling, Rock climbing, Wood carving, Computer programming

Introduction: My name is Rueben Jacobs, I am a cooperative, beautiful, kind, comfortable, glamorous, open, magnificent person who loves writing and wants to share my knowledge and understanding with you.